Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596697 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Volunteers
A Phase 1 study, sponsored by Hepion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT03596697 is a Phase 1 study that has completed, run by Hepion Pharmaceuticals. The registered enrollment target is 92 participants.
The verdict
NCT03596697, a Phase 1 study, has completed, sponsored by Hepion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is three part study that will, in part one assess the safety, tolerability, and PK of a single dose of CRV431 in healthy volunteers. The second part of the study will be a single dose drug-drug interaction study in healthy volunteers with CRV431 co-treated with TDF. The third part of the study will assess the safety, tolerability, PK, and preliminary signal for antiviral efficacy and identification of clinically-relevant biomarkers of CRV431 with TDF in stable HBV patients.
Interventions
- DRUG Placebo
- DRUG TDF
- DRUG CRV431
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2019-07-09 |
| Est. Completion | 2021-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03596697
The ClinicalTrials.gov registry entry for NCT03596697 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hepion Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03596697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03596697 about?
NCT03596697 is a clinical study titled "A Study in Healthy Volunteers". This is three part study that will, in part one assess the safety, tolerability, and PK of a single dose of CRV431 in healthy volunteers. The second part of the study will be a single dose drug-drug interaction study in healthy volunteers with CRV431 co-treated with TDF. The third part of the study ...
What is the current status of trial NCT03596697?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2019-07-09. Estimated completion is 2021-06-04.
What interventions are being tested in trial NCT03596697?
The interventions under investigation include: Placebo (DRUG), TDF (DRUG), CRV431 (DRUG).
Who is sponsoring clinical trial NCT03596697?
This trial is sponsored by Hepion Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.